A prediction model for breast cancer recurrence after adjuvant hormone therapy

P. Boracchi, D. Coradini, L. Antolini, S. Oriana, R. Dittadi, M. Gion, M. G. Daidone, Elia Biganzoli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hormone therapy with tamoxifen has long been the established adjuvant treatment for node-positive, estrogen-receptor-positive breast cancer in postmenopausal women. Since 30-40% of these patients fail to respond, reliable outcome prediction is necessary for successful treatment allocation. Using pathobiological variables (available in most clinical records: tumor size, nodal involvement, estrogen and progesterone receptor content) from 596 patients recruited at a comprehensive cancer center, we developed a prediction model which we validated in an independent cohort of 175 patients recruited at a general hospital. Calculated at 3 and 4 years of follow-up, the discrimination indices were 0.716 [confidence limits (CL) 0.641, 0.752] and 0.714 (CL 0.650, 0.750) for the training data, and 0.726 (CL 0.591, 0.769) and 0.677 (CL 0.580, 0.745) for the testing data. Waiting for more effective approaches from genomic and proteomic studies, a model based on consolidated pathobiological variables routinely assessed at relatively low costs may be considered as the reference for assessing the gain of new markers over traditional ones, thus substantially improving the conventional use of prognostic criteria.

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalInternational Journal of Biological Markers
Volume23
Issue number4
Publication statusPublished - 2008

Fingerprint

Estrogen Receptors
Hormones
Breast Neoplasms
Recurrence
Progesterone Receptors
Tamoxifen
Tumors
General Hospitals
Proteomics
Neoplasms
Testing
Therapeutics
Costs
Costs and Cost Analysis

Keywords

  • Adjuvant tamoxifen
  • Breast cancer
  • Nomogram
  • Relapse prediction

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Boracchi, P., Coradini, D., Antolini, L., Oriana, S., Dittadi, R., Gion, M., ... Biganzoli, E. (2008). A prediction model for breast cancer recurrence after adjuvant hormone therapy. International Journal of Biological Markers, 23(4), 199-206.

A prediction model for breast cancer recurrence after adjuvant hormone therapy. / Boracchi, P.; Coradini, D.; Antolini, L.; Oriana, S.; Dittadi, R.; Gion, M.; Daidone, M. G.; Biganzoli, Elia.

In: International Journal of Biological Markers, Vol. 23, No. 4, 2008, p. 199-206.

Research output: Contribution to journalArticle

Boracchi, P, Coradini, D, Antolini, L, Oriana, S, Dittadi, R, Gion, M, Daidone, MG & Biganzoli, E 2008, 'A prediction model for breast cancer recurrence after adjuvant hormone therapy', International Journal of Biological Markers, vol. 23, no. 4, pp. 199-206.
Boracchi P, Coradini D, Antolini L, Oriana S, Dittadi R, Gion M et al. A prediction model for breast cancer recurrence after adjuvant hormone therapy. International Journal of Biological Markers. 2008;23(4):199-206.
Boracchi, P. ; Coradini, D. ; Antolini, L. ; Oriana, S. ; Dittadi, R. ; Gion, M. ; Daidone, M. G. ; Biganzoli, Elia. / A prediction model for breast cancer recurrence after adjuvant hormone therapy. In: International Journal of Biological Markers. 2008 ; Vol. 23, No. 4. pp. 199-206.
@article{0fb2c72d2207488193209fc76d5c0ea2,
title = "A prediction model for breast cancer recurrence after adjuvant hormone therapy",
abstract = "Hormone therapy with tamoxifen has long been the established adjuvant treatment for node-positive, estrogen-receptor-positive breast cancer in postmenopausal women. Since 30-40{\%} of these patients fail to respond, reliable outcome prediction is necessary for successful treatment allocation. Using pathobiological variables (available in most clinical records: tumor size, nodal involvement, estrogen and progesterone receptor content) from 596 patients recruited at a comprehensive cancer center, we developed a prediction model which we validated in an independent cohort of 175 patients recruited at a general hospital. Calculated at 3 and 4 years of follow-up, the discrimination indices were 0.716 [confidence limits (CL) 0.641, 0.752] and 0.714 (CL 0.650, 0.750) for the training data, and 0.726 (CL 0.591, 0.769) and 0.677 (CL 0.580, 0.745) for the testing data. Waiting for more effective approaches from genomic and proteomic studies, a model based on consolidated pathobiological variables routinely assessed at relatively low costs may be considered as the reference for assessing the gain of new markers over traditional ones, thus substantially improving the conventional use of prognostic criteria.",
keywords = "Adjuvant tamoxifen, Breast cancer, Nomogram, Relapse prediction",
author = "P. Boracchi and D. Coradini and L. Antolini and S. Oriana and R. Dittadi and M. Gion and Daidone, {M. G.} and Elia Biganzoli",
year = "2008",
language = "English",
volume = "23",
pages = "199--206",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - A prediction model for breast cancer recurrence after adjuvant hormone therapy

AU - Boracchi, P.

AU - Coradini, D.

AU - Antolini, L.

AU - Oriana, S.

AU - Dittadi, R.

AU - Gion, M.

AU - Daidone, M. G.

AU - Biganzoli, Elia

PY - 2008

Y1 - 2008

N2 - Hormone therapy with tamoxifen has long been the established adjuvant treatment for node-positive, estrogen-receptor-positive breast cancer in postmenopausal women. Since 30-40% of these patients fail to respond, reliable outcome prediction is necessary for successful treatment allocation. Using pathobiological variables (available in most clinical records: tumor size, nodal involvement, estrogen and progesterone receptor content) from 596 patients recruited at a comprehensive cancer center, we developed a prediction model which we validated in an independent cohort of 175 patients recruited at a general hospital. Calculated at 3 and 4 years of follow-up, the discrimination indices were 0.716 [confidence limits (CL) 0.641, 0.752] and 0.714 (CL 0.650, 0.750) for the training data, and 0.726 (CL 0.591, 0.769) and 0.677 (CL 0.580, 0.745) for the testing data. Waiting for more effective approaches from genomic and proteomic studies, a model based on consolidated pathobiological variables routinely assessed at relatively low costs may be considered as the reference for assessing the gain of new markers over traditional ones, thus substantially improving the conventional use of prognostic criteria.

AB - Hormone therapy with tamoxifen has long been the established adjuvant treatment for node-positive, estrogen-receptor-positive breast cancer in postmenopausal women. Since 30-40% of these patients fail to respond, reliable outcome prediction is necessary for successful treatment allocation. Using pathobiological variables (available in most clinical records: tumor size, nodal involvement, estrogen and progesterone receptor content) from 596 patients recruited at a comprehensive cancer center, we developed a prediction model which we validated in an independent cohort of 175 patients recruited at a general hospital. Calculated at 3 and 4 years of follow-up, the discrimination indices were 0.716 [confidence limits (CL) 0.641, 0.752] and 0.714 (CL 0.650, 0.750) for the training data, and 0.726 (CL 0.591, 0.769) and 0.677 (CL 0.580, 0.745) for the testing data. Waiting for more effective approaches from genomic and proteomic studies, a model based on consolidated pathobiological variables routinely assessed at relatively low costs may be considered as the reference for assessing the gain of new markers over traditional ones, thus substantially improving the conventional use of prognostic criteria.

KW - Adjuvant tamoxifen

KW - Breast cancer

KW - Nomogram

KW - Relapse prediction

UR - http://www.scopus.com/inward/record.url?scp=65349171945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65349171945&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 199

EP - 206

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -